Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 16, 2026 to Discuss Your Rights - VTGN

Vistagen Therapeutics, Inc. (NASDAQ: VTGN) is currently facing a class action lawsuit related to alleged violations of securities laws, with the firm Levi & Korsinsky, LLP leading the charge on behalf of aggrieved investors. The lawsuit encompasses claims of securities fraud occurring between April 1, 2024, and December 16, 2025, during which Vistagen reportedly provided exaggeratedly positive statements about its Phase 3 clinical trial of fasedienol, an investigational drug intended for treating social anxiety disorder.

The complaint suggests that, while promoting the drug's potential, Vistagen concealed critical adverse information regarding the trial's outcomes. On December 17, 2025, the company announced that the Phase 3 study had failed to show a statistically significant improvement on its primary endpoint—change on the Subjective Units of Distress Scale—leading to a stark 80% drop in their stock price from $4.36 to $0.86 within a single day.

Investors who suffered losses during the designated period are encouraged to contact Levi & Korsinsky before the deadline of March 16, 2026, to investigate their eligibility to be appointed as lead plaintiffs in the case. Participation in the lawsuit incurs no out-of-pocket costs for affected investors, who may be entitled to compensation if successful.

Levi & Korsinsky has established a solid reputation in securities litigation, reportedly securing hundreds of millions in damages for shareholders over two decades. Investors seeking more information can reach out directly to the firm’s representatives via email or phone. As the case unfolds, investors will be monitoring the developments closely to assess the potential financial implications of the lawsuit and Vistagen's future prospects.

Vistagen Therapeutics, Inc. (NASDAQ: VTGN) is currently facing significant challenges following a class action lawsuit related to alleged securities law violations. Investors should approach the situation with caution, considering the recent press release and subsequent stock price collapse. On December 17, 2025, Vistagen announced that its Phase 3 PALISADE-3 trial for fasedienol, intended for treating social anxiety disorder, failed to meet its primary endpoint. This failure resulted in a staggering decline in the stock price, plummeting over 80% in a single day.

The lawsuit claims that the company's management provided misleading positive information while failing to disclose critical adverse facts about the trial results, which arguably constitutes securities fraud. As the investment community digests this information, the impact on Vistagen's financial stability and market perception could be profound.

For those currently holding Vistagen shares, it may be prudent to reassess investment strategies. The potential for further legal repercussions and financial implications could lead to increased volatility. Investors should consider limiting exposure or strategically diversifying their portfolios as a risk-mitigation measure.

Meanwhile, aggrieved investors have until March 16, 2026, to seek recourse through the lawsuit by contacting the litigation firm Levi & Korsinsky. The firm has a solid track record in securities litigation, and participating in this case may provide a path for affected investors to recover some losses without incurring direct costs.

In summary, while Vistagen's future remains uncertain amid legal troubles, investors must carefully evaluate their positions and potential outcomes, balancing risk with their tolerance levels. It may also be beneficial to monitor any updates from the company regarding its strategic direction and future clinical trials.